Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H36F3NO4 |
Molecular Weight | 555.6277 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C3=CC=C(C=C3)C(C)(C)C
InChI
InChIKey=FASLTMSUPQDLIB-MHZLTWQESA-N
InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
Molecular Formula | C32H36F3NO4 |
Molecular Weight | 555.6277 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. Adomeglivant lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Adomeglivant had been in phase II clinical trials by Eli Lilly for the treatment of type 2 diabetes mellitus. However, this research has been discontinued.
Originator
Sources: http://adisinsight.springer.com/drugs/800031719
Curator's Comment: # Eli Lilly
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02091362
Type 2 Diabetes Mellitus: single daily dose of 20 milligrams (mg) Adomeglivant (LY2409021) administered orally in 1 of 2 treatment periods.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:53:43 GMT 2023
by
admin
on
Sat Dec 16 08:53:43 GMT 2023
|
Record UNII |
74Z5ZL2KVG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000174616
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
DB11704
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
1488363-78-5
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
BC-87
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
872260-20-3
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
SUPERSEDED | |||
|
C166989
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
10202
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
74Z5ZL2KVG
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
91933867
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL3707351
Created by
admin on Sat Dec 16 08:53:43 GMT 2023 , Edited by admin on Sat Dec 16 08:53:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |